Search results for " Match"

showing 10 items of 345 documents

Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival

2022

Abstract Background An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC). Aims We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival. Methods Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching. Results The 3-months surveil…

medicine.medical_specialtyCarcinoma HepatocellularSurvivalHepatocellular carcinomaCancer stageCancer stage; Hepatocellular carcinoma; Surveillance interval; SurvivalInternal medicinemedicineHumansPropensity ScoreSurveillance intervalSurvival analysisHigh risk patientsHepatologybusiness.industryCancer stageLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAGastroenterologyPatient survivalmedicine.diseaseSurvival AnalysisHepatocellular carcinomaPropensity score matchingSurvival AnalysiLiver cancerbusinessMedian survivalHuman
researchProduct

Protective Role of Conization Before Radical Hysterectomy in Early-Stage Cervical Cancer: A Propensity-Score Matching Study.

2021

Purpose: The purpose of this study was to assess the prognostic role and the perioperative outcomes of conization performed before radical hysterectomy in early-stage cervical carcinoma. Methods: This multicenter, retrospective observational cohort study included patients with FIGO 2009 stage IB1 cervical carcinoma treated with radical hysterectomy between June 2004 and June 2019. Patients were divided into two groups according to conization before radical surgery. One-to-one case–control matching was used to adjust the baseline characteristics. Results: A total of 332 patients were included after propensity matching (166, 50% in each group). Twenty-four of 166 (14.4%) and 142 of 166 (85.6%…

medicine.medical_specialtyConizationUterine Cervical NeoplasmsHysterectomy03 medical and health sciences0302 clinical medicineMedicineHumansRisk factorStage (cooking)Radical surgeryRadical HysterectomyNeoplasm StagingRetrospective StudiesCervical cancerbusiness.industryPerioperativemedicine.diseaseSurgeryNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIALocalOncology030220 oncology & carcinogenesisPropensity score matchingCervical cancer030211 gastroenterology & hepatologySurgeryFemaleNeoplasm Recurrence LocalbusinessCohort studyAnnals of surgical oncologyREFERENCES
researchProduct

Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patient…

2018

Introduction The biodegradable polymer drug-eluting stents were developed to improve vascular healing. However, further data are needed to confirm the safety and efficacy of these stents in patients with acute myocardial infarction (AMI). Aim We sought to determine the 1-year clinical follow-up in patients with AMI treated with a thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus a durable coating everolimus-eluting stent (DP-EES). Material and methods We analyzed patients with AMI (STEMI and NSTEMI) treated with either a BP-SES (ALEX, Balton, Poland, n = 886) or DP-EES (XIENCE, Abbott, USA, n = 1054) with available 1-year clinical follow-up using propensity sco…

medicine.medical_specialtyEverolimus eluting stentmedicine.medical_treatmentacute myocardial infarctionlcsh:Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineIn patientcardiovascular diseases030212 general & internal medicineMyocardial infarctionOriginal Paperbusiness.industrylcsh:Rdrug-eluting stentsStentPercutaneous coronary interventionequipment and suppliesmedicine.diseaseBiodegradable polymerSurgerybioabsorbable polymerSirolimusPropensity score matchingCardiology and Cardiovascular Medicinebusinessmedicine.drugAdvances in Interventional Cardiology
researchProduct

1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents

2016

Abstract Objectives The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention. Background Randomized studies of the ABSORB BRS have been performed in selected patient and lesion scenarios. The available registries of the ABSORB BRS reflect real-world practice more closely compared with randomized studies, but most of them are limited by the small sample size and the lack of comparative outcomes versus second-generation drug-eluting stents. Methods A total of 1,189 …

medicine.medical_specialtyEverolimusbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionStent030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineInternal medicinePropensity score matchingConventional PCIClinical endpointmedicineCardiology030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.drugJACC: Cardiovascular Interventions
researchProduct

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

2009

Objective: Recent findings support greater efficacy of early vs. delayed interferon beta (IFN) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFN treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFN treatment with regard to the greatest benefits on disability progression. Methods: A cohort of 2,570 IFN-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients with early vs. dela…

medicine.medical_specialtyExpanded Disability Status Scalebusiness.industryMultiple sclerosisHazard ratiomedicine.diseaseSurgeryCentral nervous system diseaseNeurologyInternal medicinePropensity score matchingCohortmedicineObservational studyNeurology (clinical)Unmeasured confoundingbusinessAnnals of Neurology
researchProduct

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C

2012

Summary.  Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naive patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400  mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44…

medicine.medical_specialtyHepatitis C virusPopulationmacromolecular substancesmedicine.disease_causeGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawVirologyInternal medicineMedicineeducationeducation.field_of_studyHepatologybusiness.industryRibavirintechnology industry and agriculturevirus diseasesmedicine.diseasedigestive system diseasesMenopauseInfectious DiseasesEndocrinologychemistryPropensity score matchingSteatosisMetabolic syndromebusinessJournal of Viral Hepatitis
researchProduct

Perioperative chemotherapy versus surgery alone for resectable colorectal liver metastases: an international multicentre propensity score matched ana…

2021

Abstract Background There is still uncertainty regarding the role of perioperative chemotherapy (CTx) in patients with resectable colorectal liver metastases (CRLM), especially in those with a low-risk of recurrence. Methods Multicentre retrospective analysis of patients with CRLM undergoing liver resection between 2010–2015. Patients were divided into two groups according to whether they received perioperative CTx or not and were compared using propensity score matching (PSM) analysis. Then, they were stratified according to prognostic risk scores, including: Clinical Risk Score (CRS), Tumour Burden Score (TBS) and Genetic And Morphological Evaluation (GAME) score. Results The study includ…

medicine.medical_specialtyIndependent predictorResection03 medical and health sciences0302 clinical medicineRisk FactorsPerioperative chemotherapyLong term outcomesmedicineOverall survivalHepatectomyHumansPropensity ScoreRetrospective StudiesHepatologybusiness.industryLiver NeoplasmsGastroenterologyPerioperativePrognosisSurgery030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyNeoplasm Recurrence LocalColorectal NeoplasmsbusinessClinical risk factorHPB
researchProduct

058 THE ROLE OF FEMALE SEX IN THE CONTEMPORARY TREATMENT OF THE LEFT MAIN CORONARY ARTERY INSIGHTS FROM THE W-DELTA (WOMEN-DRUG ELUTING STENT FOR LEF…

2013

Background The optimal revascularization strategy of women with unprotected left main coronary artery (ULMCA) disease is unknown. Therefore, the aim of this study was to evaluate long-term clinical outcomes in this cohort treated with percutaneous coronary intervention (PCI) utilising drug-eluting stents (DES) versus coronary artery bypass grafting (CABG). Methods All consecutive women from the Drug Eluting stent for LefT main coronary Artery disease (DELTA) Registry with ULMCA disease treated by PCI with DES or CABG were analysed. A propensity matching was performed to adjust for baseline differences between the 2 treatment groups. Results In total, 818 women were included: 489 (59.8%) und…

medicine.medical_specialtyInterventional cardiologybusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionRevascularizationmedicine.diseaseDrug-eluting stentInternal medicineConventional PCIPropensity score matchingCardiologymedicinecardiovascular diseasesMyocardial infarctionCardiology and Cardiovascular MedicinebusinessStrokeHeart
researchProduct

Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large m…

2020

Abstract Background Aim of this study was to evaluate and compare perioperative outcomes of transperitoneal (TP) and retroperitoneal (TR) approaches in a multi-institutional cohort of minimally invasive partial nephrectomy (MI-PN). Material and methods All consecutive patients undergone MI-PN for clinical T1 renal tumors at 26 Italian centers (RECORd2 project) between 01/2013 and 12/2016 were evaluated, collecting the pre-, intra-, and postoperative data. The patients were then stratified according to the surgical approach, TP or RP. A 1:1 propensity score (PS) matching was performed to obtain homogeneous cohorts, considering the age, gender, baseline eGFR, surgical indication, clinical dia…

medicine.medical_specialtyIntraoperative ComplicationUrologymedicine.medical_treatmentOperative TimeSurgical approach030232 urology & nephrologyMinimally invasive partial nephrectomy Renal cell carcinoma Retroperitoneal Surgical approach Transperitoneal.lcsh:RC870-923lcsh:RC254-282NephrectomyArticle03 medical and health sciences0302 clinical medicineRenal cell carcinomamedicineMinimally invasive partial nephrectomy; Renal cell carcinoma; Retroperitoneal; Surgical approach; TransperitonealHumansRetroperitoneal SpaceRetrospective StudiesMinimally invasive partial nephrectomybusiness.industryRenal cell carcinoma; Minimally invasive partial nephrectomy; Transperitoneal; Retroperitoneal; Surgical approachTransperitonealPerioperativeRetroperitoneallcsh:Diseases of the genitourinary system. Urologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseNephrectomyKidney NeoplasmsRenal cell carcinomaSurgerySettore MED/24Treatment Outcome030220 oncology & carcinogenesisPropensity score matchingCohortSurgeryLaparoscopyPositive Surgical MarginMinimally invasive partial nephrectomy; Renal cell carcinoma; Retroperitoneal; Surgical approach; Transperitoneal; Follow-Up Studies; Humans; Nephrectomy; Operative Time; Retroperitoneal Space; Retrospective Studies; Treatment Outcome; Kidney Neoplasms; LaparoscopybusinessAbdominal surgeryFollow-Up StudiesSurgical endoscopy
researchProduct

Comparison of One-Year Outcomes Between the ihtDEStiny BD Stent and the Durable-Polymer Everolimus- and Zotarolimus-Eluting Stents: A Propensity-Scor…

2021

Abstract Objectives We sought to evaluate clinical outcomes in patients treated with the drug-eluting stent ihtDEStiny BD. Background The ihtDEStiny BD stent is a metallic sirolimus eluting stent with a biodegradable polymer with both drug and polymer coating the abluminal surface of the stent and balloon. Methods In this study, the clinical outcomes of a multicenter prospective registry of patients treated with this stent (DEStiny group) were analyzed and compared with those of a control group of patients treated with durable polymer everolimus or zotarolimus eluting stents (CONTROL group) paired by propensity score matching . Primary outcome was the target vessel failure (TVF) at 12 month…

medicine.medical_specialtyPolymersmedicine.medical_treatment030204 cardiovascular system & hematologyProsthesis DesignCoronary artery disease03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionAbsorbable ImplantsmedicineClinical endpointHumansZotarolimus030212 general & internal medicineMyocardial infarctionEverolimusPropensity ScoreSirolimusEverolimusbusiness.industryStentDrug-Eluting StentsGeneral Medicinemedicine.diseaseSurgeryTreatment OutcomeDrug-eluting stentPropensity score matchingCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiovascular revascularization medicine : including molecular interventions
researchProduct